Article
EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in…
medRxiv · 2021 · Kai Voeltzke
Key facts
| Title | EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma |
|---|---|
| First author | Kai Voeltzke |
| Journal | medRxiv |
| Published | Dec 9, 2021 |
| DOI | 10.1101/2021.12.08.471784 |
| Devices mentioned | K042884, K800781, K810863 |
| Product codes mentioned | DBM, JCJ, JJH, KPA, MVU, MYA, MXZ, NJT, NKF, KIS |
At a glance
- 1–9 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1